1D-LSD
Pharmaceutical compound
From Wikipedia, the free encyclopedia
1D-LSD, also known as 1-(1,2-dimethylcyclobutane-1-carbonyl)-LSD or as SYN-L-229, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1] It is believed to be a prodrug of LSD and replaced 1V-LSD in Germany after 1V-LSD became covered by the German NpSG law in 2022.[2][1]
- None
 | |
 | |
| Clinical data | |
|---|---|
| Other names | 1-(1,2-Dimethylcyclobutane-1-carbonyl)-LSD; 1-(1,2-Dimethylcyclobutane-1-carbonyl)-N,N-diethyllysergamide; SYN-L-229 |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | 6–8 hours[1] |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C27H35N3O2 |
| Molar mass | 433.596 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Use and effects
1D-LSD has a dose of 10 to 350 μg depending on the intended use, with blotter tabs typically containing 150 μg.[1] It is said to be roughly comparable in potency to 1V-LSD.[1] 1D-LSD is said to have a much faster onset than 1V-LSD or LSD but to also have a shorter duration in comparison (6–8 hours and 10–12 hours, respectively).[1]
Interactions
Chemistry
History
1D-LSD was encountered online as a novel designer drug in October 2022 after 1V-LSD was prohibited in Germany in September 2022.[1]
Society and culture
Legal status
Austria
According to the current legal situation, 1D-LSD is neither explicitly mentioned in the Narcotic Drugs Ordinance nor in the Psychotropic Substances Ordinance (SV/PV), thus it is neither to be classified as a narcotic drug in the sense of the SV nor as a psychotropic substance in the sense of the PV.
Canada
1D-LSD is not a controlled substance in Canada as of 2025.[3]
Germany
Since the 14 June 2024 1D-LSD (and 1T-LSD) are covered by the German NpSG law.
United States
1D-LSD is not an explicitly controlled substance in the United States.[4] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.